Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
about
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer TherapyInducing Oncoprotein Degradation to Improve Targeted Cancer TherapyPhosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancerA Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung CancerBH4 domain of Bcl-2 as a novel target for cancer therapyMolecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized TherapyUpdate on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.Allosteric therapies for lung cancer.Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.Modulation of Bax and mTOR for Cancer Therapeutics.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.
P2860
Q24337757-DAF4F75F-41FA-4165-8FD1-F157D2F52C09Q26782145-90FAD085-BD89-425F-8D97-93535D04C3D0Q35256618-5D41389D-8EB7-4555-87C2-4182A5D08E7FQ35463464-1F09F67A-65B7-431F-8CF2-BD54A7F1415EQ36940766-EF957BFC-34DF-49D4-90F8-8F01BDB052D4Q37347532-CCE9E607-B390-4CE1-835A-CB68749D5A1AQ37721218-3889F7B8-BDA8-4FD1-9A76-34B73B78B758Q37733727-B949DF89-9D32-4E28-ADA1-AF352ED179B1Q37743107-BD3D4766-771C-4D99-813D-D52CE206F69AQ38268170-780AA7B9-CB6B-4E53-B4BB-37E75E51C458Q38465098-51B632D1-5A41-4203-94A7-986089685B4AQ38515841-D8BBEB73-0572-4F96-984A-9DEC829DDBB4Q39220897-C1B2C203-B022-4E8E-BD8B-C80DCA5EA617Q46342083-CCD6A686-0A49-42FA-AB7E-018AD0A664B8Q50662513-CFDC7269-52D4-47F6-8D89-4DFE87818C40Q51122180-B6C840F7-3BB3-4770-8A7B-B87B3A497A69Q51272851-44822CDC-E105-414B-81F2-C9BB745F16D1Q55104021-387C4A79-815B-4032-9190-F17D26D59565
P2860
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@ast
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@en
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@nl
type
label
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@ast
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@en
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@nl
prefLabel
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@ast
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@en
Phase II study of docetaxel in ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P1476
Phase II study of docetaxel in ...... ced non-small-cell lung cancer
@en
P2093
Anthony A Gal
Carmen M Klass
Dong M Shin
Fadlo R Khuri
Gabriel Sica
Janakiraman Subramanian
Madhusmita Behera
Nabil F Saba
R Donald Harvey
P2860
P304
P356
10.1097/JTO.0B013E318282709C
P577
2013-03-01T00:00:00Z